Electromed, Inc. Announces Fiscal 2019 Fourth Quarter and Full Year Financial Results -- Fourth quarter results driven by 10.1% year-over-year growth in home care revenue and operating margin improv

Inc. Announces Fiscal 2019 Fourth Quarter and Full Year Financial Results

Fourth quarter results driven by 10.1% year-over-year growth in home care revenue and operating margin improvement to 17.3% --

Prague, Minnesota - August 27, 2019 - Electromed, Inc. (NYSE American: ELMD), a leader in innovative airway clearance

technologies, today announced financial results for the three months ended June 30, 2019 (Q4 FY 2019).

Skarvan, President and Chief Executive Officer of Electromed, commented, "In the fourth quarter of fiscal 2019, we delivered

record revenue of $8.6 million, driven by a 10.1% year-over-year increase in home care revenue. Moreover, we achieved strong growth

in operating income and cash flow from operating activities, reflecting our continuing cost containment efforts and the sales

force restructuring we implemented in March 2019. Regarding our emphasis on sales force productivity, this quarter we produced

approximately $908,000 of annualized home care revenue per direct field sales employee, exceeding our target range of between

$750,000 and $850,000. While quarter to quarter fluctuations in our business can be expected, in fiscal 2020 we are confident

about attaining target productivity levels and low double-digit revenue growth."

Skarvan continued, "Educating physicians on the value of SmartVest Airway Clearance therapy for bronchiectasis patients

is key to our growth. This quarter BMC Pulmonary Medicine published a first-of-its-kind independent study that concluded

early initiation of therapy with SmartVest decreases severe exacerbations, reduces antibiotic use and stabilizes lung function

for bronchiectasis patients. This study along with published outcomes studies in Respiratory Therapy in 2016 and 2018 demonstrate

the growing body of clinical evidence supporting the use of our SmartVest Airway Clearance device as a standard of care among

individuals with non-Cystic Fibrosis Bronchiectasis. Guided by our patient-centric mission of making life's important moments

possible, one breath at a time, we aim to further penetrate the large and growing bronchiectasis market."

revenue increased 9.3% to $8.6 million, from $7.9 million in Q4 FY 2018, primarily driven by higher home care revenue. Home care

revenue rose 10.1% to $8.0 million from $7.3 million in Q4 FY 2018, primarily due to a higher average allowable due to payor mix

as compared to the prior year and greater productivity from the Company's field sales staff. Field sales employees totaled

40, of which 34 were direct sales, at the end of Q4 FY 2019, compared to 42 at the end of Q3 FY 2019, of which 36 were direct

sales, and 50 at the end of Q4 FY 2018 of which 42 were direct sales.

profit increased 8.1% to $6.7 million, or 77.5% of net revenue, from $6.2 million, or 78.4% of net revenue, in Q4 FY 2018. The

increase in gross profit resulted primarily from an increase in home care revenue. The decrease in gross profit as a percentage

of net revenue was driven by a lower selling price per device in our institutional market.

expenses, which include selling, general and administrative (SG&A) as well as R&D expenses, totaled $5.2 million,

or 60.2% of net revenue, compared with $4.9 million, or 62.3% of net revenue, in the same period of the prior year.

SG&A expenses increased by $212,000 to $5.1 million from $4.9 million in Q4 FY 2018. The prior year quarter benefited

from a refund of a medical device tax that reduced Q4 FY 2018 SG&A expense by $406,000 while the current year included

additional depreciation and amortization of $117,000 due to terminating a lease of office space, requiring us to accelerate

the leasehold amortization associated with the property. As a percentage of revenue, SG&A expenses improved to

59.0% compared to 61.8%, reflecting ongoing cost-containment efforts. R&D expenses increased to $107,000, from $41,000 in

Q4 FY 2018, due to work on an innovative product feature designed to improve patients' access to treatment

income totaled $1.5 million, compared to $1.3 million in Q4 FY 2018.

income before income tax expense totaled $1.5 million compared to $1.3 million in Q4 FY 2018.

income equaled $1.1 million, or $0.13 per diluted share, compared to $1.0 million, or $0.11 per diluted share, in Q4 FY 2018.

In Q4 FY 2019, income tax expense totaled $432,000, compared to $339,000 in the same period of the prior year.

2019 Full Year Summary

the fiscal year ended June 30, 2019, revenue grew 10.6% to $31.3 million, from $28.3 million in fiscal 2018, driven by a 10.3%

increase in home care revenue. Gross margins were 76.2%, compared to 76.9% in the prior fiscal year, while net income was approximately

$2.0 million, or $0.23 per diluted share, compared to approximately $1.8 million, or $0.21 per diluted share, in fiscal 2018.

Company's balance sheet at June 30, 2019 included cash of $7.8 million, no debt, working capital of $20.9 million, and shareholders'

equity of $25.7 million.

will host a conference call on August 28, 2019 at 8:00 am CT (9:00 am ET) to discuss Q4 FY 2019 financial results and other matters.

parties may participate in the call by dialing:

conference call will also be accessible via the following link:

those who cannot listen to the live broadcast, an online webcast replay will be available in the Investor Relations section of

the Company's web site at: http://investors.smartvest.com/

Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest

Airway Clearance System, to patients with compromised pulmonary function. The Company is headquartered in New Prague, Minnesota

and was founded in 1992. Further information about the Company can be found at www.smartvest.com.

statements in this release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act

of 1995. Forward-looking statements can generally be identified by words such as "believe," "estimate,"

"expect," "may," "plan" "potential," "should," "will,"

and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements.

Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known

or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to:

the competitive nature of our market; risks associated with expansion into international markets; changes to Medicare, Medicaid,

or private insurance reimbursement policies; new drug or pharmaceutical discoveries; changes to health care laws; changes affecting

the medical device industry; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances;

our ability to protect and expand our intellectual property portfolio; our ability to renew our line of credit or obtain additional

credit as necessary; our ability to develop new sales channels for our product; and general economic and business conditions,

as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including the Company's

most recent Annual Report on Form 10-K, as amended from time to time, and subsequent reports on Form 10-Q and Form 8-K). Investors

should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate

assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place

undue reliance on "forward-looking statements," as such statements speak only as of the date of this release.

Statements of Operations

Statements of Cash Flows